SCHEMBL3435989

SCHEMBL3435989

CCn1nc(-c2ccc(Cl)cc2OC)cc1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MARS1 P56192 4/20 0.46
USP2 O75604 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
TP53 P04637 2/20 0.43
MDM2 Q00987 2/20 0.43
ALDH1A1 P00352 3/20 0.43
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
MAPK1 P28482 1/20 0.41
PIK3CA P42336 1/20 0.41
MAPK8 P45983 1/20 0.41
MAPK9 P45984 1/20 0.41
MAPK10 P53779 1/20 0.41
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
TSHR P16473 1/20 0.40
RECQL P46063 1/20 0.40
NPC1 O15118 1/20 0.40
CCR2 P41597 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3435083 0.86 KMT2A (0.47) USP2HTTKMT2ATP53ALDH1A1
SCHEMBL3436594 0.85 KMT2A (0.44) USP2HTTKMT2ATP53MDM2
SCHEMBL3436589 0.85 MARS1 (0.58) MARS1HTTMAPTNPC1
SCHEMBL3436592 0.84 CYP1A2 (0.44) MARS1USP2HTTKMT2ATP53
SCHEMBL3434182 0.84 ALDH1A1 (0.48) TP53MDM2ALDH1A1MAPTHPGD
SCHEMBL3435955 0.81 CNR1 (0.43) MARS1USP2HTTKMT2AALDH1A1
SCHEMBL10049095 0.80 HSP90AA1 (0.43) MARS1TP53MDM2ALDH1A1HSP90AA1
SCHEMBL19936567 0.78 HSP90AA1 (0.43) TP53MDM2ALDH1A1HSP90AA1HSP90AB1
SCHEMBL19936673 0.76 HSP90AA1 (0.40) TP53MDM2ALDH1A1HSP90AA1HSP90AB1
SCHEMBL1739252 0.76 ALPL (0.46) MARS1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI MARS1 2935/4885USP2 1343/4885HTT 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.